Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

All talk, no M&A makes for a down JPM Day

  • Adam Feuerstein

By Adam Feuerstein Jan. 13, 2020

Reprints
JPM 2020 Lombard St
Alex Hogan/STAT

SAN FRANCISCO — Monday at the J.P. Morgan Healthcare Conference came and went without significant buyouts or deals, and so, biotech stocks fell.

The sector’s most closely followed stock index closed down 2%. Gene therapy developer Uniqure (QURE) — high on many investors’ takeout list — was among the sector’s biggest Monday losers. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
‘What could help me to die?’ Doctors clash over…
‘What could help me to die?’ Doctors clash over euthanasia
INTERACTIVE: Explore how illegal drugs have become cheaper and…
INTERACTIVE: Explore how illegal drugs have become cheaper and more potent over time
Former J&J exec, an in-demand free agent, takes the…
Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma
Is there $21 billion left for Covid response, or…
Is there $21 billion left for Covid response, or $5 billion? The White House is using…
Dutch health minister won’t cover a Gilead cancer drug…
Dutch health minister won’t cover a Gilead cancer drug due to the cost

Recommended Stories